Maverick Capital’s AtriCure ATRC Stock Holding History

Maverick Capital’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,267	Closed	-$339K	–	646
2021 Q2	$339K	Sell	4,267 -1,744	-29%	-$127K	﹤0.01%	425
2021 Q1	$394K	Buy	+6,011	New	+$370K	﹤0.01%	405

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital's ATRC Position: Q3 2021 in Review

Maverick Capital sold out of AtriCure (ATRC) in Q3 2021, closing a stake of 4,267 shares — an estimated $339K sold.

Maverick Capital first reported a position in ATRC in Q1 2021 and held it in 2 quarters. The position peaked at $394K in Q1 2021. 213 funds tracked by Wall St. Rank hold ATRC as of Q3 2021.

Maverick Capital reported no remaining AtriCure position as of Q3 2021 after selling out during the quarter.
Maverick Capital sold 4,267 AtriCure shares in Q3 2021, an estimated $339K.
Maverick Capital first reported a position in AtriCure in Q1 2021 and held it in 2 quarters.
Maverick Capital's AtriCure position peaked at $394K in Q1 2021.
213 funds tracked by Wall St. Rank held AtriCure as of Q3 2021.

Based on Maverick Capital's 13F filing for Q3 2021, filed 15 Nov 2021.